There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Longeveron (LGVN – Research Report), Optinose (OPTN – Research Report) and Actinium Pharmaceuticals (ATNM – Research Report) with bullish sentiments.
Longeveron (LGVN)
H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Longeveron today and set a price target of $12.00. The company’s shares closed last Friday at $1.75, close to its 52-week low of $1.60.
According to TipRanks.com, Selvaraju is a 4-star analyst with an average return of
Longeveron has an analyst consensus of Moderate Buy, with a price target consensus of $12.00.
See the top stocks recommended by analysts >>
Optinose (OPTN)
In a report released today, Matthew Caufield from H.C. Wainwright reiterated a Buy rating on Optinose, with a price target of $5.00. The company’s shares closed last Friday at $0.86, close to its 52-week low of $0.80.
According to TipRanks.com, Caufield is a 4-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Optinose with a $4.00 average price target, representing a 346.8% upside. In a report issued on April 26, Lake Street also maintained a Buy rating on the stock.
Actinium Pharmaceuticals (ATNM)
H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Actinium Pharmaceuticals today and set a price target of $50.00. The company’s shares closed last Friday at $6.87.
According to TipRanks.com, Pantginis is a 4-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Actinium Pharmaceuticals with a $30.50 average price target, a 363.5% upside from current levels. In a report issued on April 18, JonesTrading also maintained a Buy rating on the stock with a $26.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on LGVN:
- Longeveron to Present at the Planet MicroCap Showcase
- Longeveron Bolsters Market Position with Strategic Financing
- Longeveron Raises a Total of $11.4 Million in Gross Proceeds from Warrant Exercise Offering and Public Offering
- Longeveron announces exercise of warrants for $6.2M gross proceeds
- Longeveron Announces Exercise of Warrants for $6.2 Million Gross Proceeds
